more

Maravai LifeSciences (MRVI)

(Real Time Quote from BATS)

$10.69 USD

+0.16 (1.52%)

Updated May 14, 2024 02:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

Bottom 43% (142 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Maravai LifeSciences Holdings, Inc. (MRVI) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research Published on February 25,2022

Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

MRVIPositive Net Change

Can Maravai LifeSciences Holdings, Inc. (MRVI) Climb 56% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research Published on February 24,2022

The consensus price target hints at a 55.8% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MRVIPositive Net Change

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on February 23,2022

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 18.42% and 10.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on February 09,2022

Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is Maravai LifeSciences Holdings, Inc. (MRVI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on December 28,2021

Here is how Maravai LifeSciences Holdings, Inc. (MRVI) and Repligen (RGEN) have performed compared to their sector so far this year.

3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022

by Debanjana Dey Published on December 21,2021

Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.

Philips (PHG) to Buy Vesper Medical, Expand Vascular Portfolio

by Zacks Equity Research Published on December 15,2021

Philips (PHG) is set to acquire Vesper Medical to strengthen its vascular devices portfolio and customer base.

Is LabCorp (LH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on December 10,2021

Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.

Earnings Estimates Moving Higher for Maravai LifeSciences Holdings, Inc. (MRVI): Time to Buy?

by Zacks Equity Research Published on December 06,2021

Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

MRVIPositive Net Change

Can Maravai LifeSciences Holdings, Inc. (MRVI) Climb 25% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research Published on December 06,2021

The consensus price target hints at a 25.1% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MRVIPositive Net Change

Has LabCorp (LH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on November 24,2021

Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.

How Much Upside is Left in Maravai LifeSciences (MRVI)? Wall Street Analysts Think 40%

by Zacks Equity Research Published on November 15,2021

The consensus price target hints at a 40.2% upside potential for Maravai LifeSciences (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MRVIPositive Net Change

New Strong Buy Stocks for October 8th

by Zacks Equity Research Published on October 08,2021

CNXC, DLTH, NVEE, MRVI, and PFSI have been added to the Zacks Rank #1 (Strong Buy) List on October 8, 2021.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on October 07,2021

Faster adoption of digital health and an improved business environment are expected to have contributed to Walgreens' (WBA) fourth-quarter performance.

3 High-Potential MedTech Stocks With More Than 50% Growth YTD

by Riya Anand Published on September 29,2021

Stocks like West Pharmaceuticals Services (WST), Maravai LifeSciences (MRVI) and Option Care Health (OPCH) have gained stupendously year to date.

Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research Published on August 30,2021

Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Top Ranked Momentum Stocks to Buy for August 13th

by Zacks Equity Research Published on August 13,2021

MRVI, DSKE, VRTS, and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 13, 2021.

NVIDIA, Lumentum, Maravai LifeSciences, Baxter International and BellRing Brands highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research Published on July 06,2021

NVIDIA, Lumentum, Maravai LifeSciences, Baxter International and BellRing Brands highlighted as Zacks Bull and Bear of the Day

Child Health in Focus in Face of Delta Strain Threat: 3 Picks

by Urmimala Biswas Published on July 02,2021

Here are three stocks, BAX, BRBR, and MRVI with a favorable Zacks Rank and huge prospects in child healthcare at present.

medical

The Zacks Analyst Blog Highlights: Henry Schein, BellRing Brands, Maravai LifeSciences and National Vision Holdings

by Zacks Equity Research Published on June 28,2021

The Zacks Analyst Blog Highlights: Henry Schein, BellRing Brands, Maravai LifeSciences and National Vision Holdings

medical

4 Safe MedTech Bets Before Delta Strain Disrupts the Market Again

by Urmimala Biswas Published on June 25,2021

Here are four MedTech stocks, HSIC, BRBR, MRVI and EYE, with favorable Zacks Rank and stellar growth parameters.

medical

The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein

by Zacks Equity Research Published on June 11,2021

The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein

medical

5 MedTech Stocks to Gain in 2021 as Base Business Recovers

by Urmimala Biswas Published on June 10,2021

These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.

medical